EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study

Jason Bacharach, Eugene B McLaurin, Steven Silverstein iD, Mourad Amrane, Jean-Sebastien Garrigue, Dahlia Ismail, William J Flynn, Catiolanze Phase 2 study group

Journal of Ocular Pharmacology and Therapeutics · 2024

DOI: 10.1089/jop.2024.0029 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Ocular Pharmacology and Therapeutics, 2024. Verfasst von Jason Bacharach und 7 weiteren Autor:innen. Beteiligte Einrichtung: North Bay Eye Associates, Petaluma, California, USA. Hauptthemen laut MEDLINE: Glaucoma, Open-Angle, Latanoprost, Intraocular Pressure, Preservatives, Pharmaceutical. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To compare intraocular pressure (IOP), ocular surface disease (OSD) parameters, and safety in patients with open-angle glaucoma (OAG)/ocular hypertension (OH) and concurrent OSD treated with preservative-free latanoprost 0.005% cationic emulsion (PF-latanoprost-E) or travoprost-Z 0.004% ophthalmical solution containing a soft preservative system.

Methods

Patients with OAG/OH and OSD were randomized to treatment with PF-latanoprost-E or travoprost-Z nightly for 3 months. Outcomes included mean diurnal IOP reduction; OSD endpoints, including symptom improvement, tear break-up time (TBUT), and corneal fluorescein staining (CFS) score; and safety after 1 and 3 months.

Results

A total of 105 patients were randomized, 51 to PF-latanoprost-E and 54 to travoprost-Z. IOP reductions (LS mean differences) at 3 months were numerically greater in the PF-latanoprost-E than in the travoprost-Z group at 8AM (7.2 versus 6.0 mmHg), 10AM (6.7 versus 5.9 mmHg), and 4PM (6.0 versus 5.4 mmHg). LS mean changes in IOP from baseline in both groups at 1 and 3 months, however, were comparable. Mean ± SD CFS scores on the Ora scale at month 3 showed significantly greater reductions in the PF-latanoprost-E than in the travoprost-Z group (–1.07 ± 1.863 versus –0.16 ± 2.553 P = 0.0461). The mean TBUT at month 3 showed similar improvements in both groups (1.1 versus 1.0 s, P > 0.05). OSD symptoms improved but did not differ significantly in the two groups. Overall safety was comparable in both groups.

Conclusion

PF-latanoprost-E effectively and safely lowered IOP and improved OSD parameters in patients with OAG/OH. These findings provide evidence for the beneficial effects of this new formulation of latanoprost in glaucoma patients with OSD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glaucoma, Open-AngleLatanoprostIntraocular PressurePreservatives, PharmaceuticalAntihypertensive AgentsOphthalmic SolutionsEmulsionsHumansMaleFemaleMiddle AgedAgedOcular HypertensionTravoprostCationsTreatment OutcomeDry Eye Syndromes

Stichwörter der Autor:innen

cationic emulsionlatanoprostopen-angle glaucoma

Substanzen

LatanoprostPreservatives, PharmaceuticalAntihypertensive AgentsOphthalmic SolutionsEmulsionsTravoprostCations

Autor:innen und Institutionen

  • North Bay Eye Associates, Petaluma, California, USA.
  • Total Eye Care, P.A., Memphis, Tennessee, USA.
  • Silverstein Eye Centers, Kansas City, Missouri, USA.
  • Santen Pharmaceuticals, Paris, France.
  • R and R Eye Research, LLC, San Antonio, Texas, USA.

ORCID-Profile: Steven Silverstein

Zitieren

APA

Bacharach, J., McLaurin, E. B., Silverstein, S., Amrane, M., Garrigue, J. S., Ismail, D., Flynn, W. J., & Catiolanze Phase 2 study group (2024). Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study. Journal of Ocular Pharmacology and Therapeutics. https://doi.org/10.1089/jop.2024.0029

Vancouver

Bacharach J, McLaurin EB, Silverstein S, Amrane M, Garrigue JS, Ismail D, et al. Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study. Journal of Ocular Pharmacology and Therapeutics. 2024. doi:10.1089/jop.2024.0029

BibTeX
@article{Bacharach2024,
  author = {Bacharach, Jason and McLaurin, Eugene B and Silverstein, Steven and Amrane, Mourad and Garrigue, Jean-Sebastien and Ismail, Dahlia and Flynn, William J and Catiolanze Phase 2 study group, Catiolanze Phase 2 study group},
  title = {Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study},
  journal = {Journal of Ocular Pharmacology and Therapeutics},
  year = {2024},
  doi = {10.1089/jop.2024.0029}
}
Kostenlos starten →